Showing results (41-50 of 552) with videos related to
Sort By:
Pageof 56
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B AtkinsThe Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B AtkinsCurrent Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunotherapeutic approaches for the treatment of malignant melanomaC Curiel-Lewandrowski, M B AtkinsSeminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B AtkinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B AtkinsNature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B AtkinsOncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B AtkinsCurrent Opinion in Cardiology|December 3, 2021
Arrhythmogenic right ventricular cardiomyopathy in the pediatric populationMitchell I Cohen, Melany B AtkinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Rapid development of hypertension by sorafenib: toxicity or target?Benjamin D Humphreys, Michael B AtkinsCell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|July 1, 1995
Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriolK B Atkins, B R TroenPageof 56